Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

GLP-1 drugs such as Ozempic and Mounjaro have been heralded as some of the most important drug breakthroughs ever.

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

The following is a summary of “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis,” published in the November ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.